Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Reportlinker Adds Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs


      News provided by

      Reportlinker

      Dec 08, 2010, 02:00 ET

      Share this article

      Share this article


      NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

      Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

      http://www.reportlinker.com/p0336653/Diabetes-Market-to-2016---Biguanides-and-Insulin-Analogs-will-be-the-Largest-Selling-Anti-Diabetic-Drugs.html

      Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

      Summary

      GBI Research's new report, "Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs", provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

      This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

      Scope

      The scope of this report includes:

      - Annualized market data for the diabetes therapeutics market from 2001 to 2009, forecast forward to 2016.

      - Market characterization of the diabetes therapeutics market, including market size, annual cost of therapy and treatment usage patterns.

      - Key drivers and barriers that have a significant impact on the market.

      - Coverage of pipeline molecules in various phases of drug development. .

      - Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global diabetes therapeutics market.

      Reasons to buy

      The report will enhance your decision making capability. It will allow you to

      - Align your product portfolio to the markets with high growth potential.

      - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

      - Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

      - Develop key strategic initiatives by understanding the key focus areas of leading companies.

      - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

      1 Table of Contents 3

      1.1 List of Tables 6

      1.2 List of Figures 8

      2 Global Diabetes Market: Introduction 10

      2.1 GBI Research Report Guidance 10

      3 Global Diabetes Market: Market Overview 11

      3.1 Introduction 11

      3.2 Unmet Needs 11

      3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs 11

      3.2.2 Carcinogenic Effects Associated With Insulin Analogs 12

      3.2.3 Poor Patient Compliance 12

      3.3 Revenue 12

      3.4 Annual Cost of Therapy 14

      3.5 Treatment Usage Patterns 15

      3.5.1 Diseased Population 17

      3.5.2 Treatment Seeking Population 18

      3.5.3 Diagnosed Population 19

      3.5.4 Prescription Population 20

      3.6 Drivers and Restraints of Diabetes Market 21

      3.6.1 Drivers of Diabetes Market 21

      3.6.2 Restraints of Diabetes Market 21

      4 Global Diabetes Market: Geographical Landscape 23

      4.1 The US 25

      4.1.1 Revenue 25

      4.1.2 Annual Cost of Therapy 27

      4.1.3 Treatment Usage Patterns 28

      4.2 Top Five EU Countries 33

      4.2.1 Revenue 33

      4.2.2 Annual Cost of Therapy 35

      4.2.3 Treatment Usage Patterns 36

      4.3 Japan 41

      4.3.1 Revenue 41

      4.3.2 Annual Cost Therapy 42

      4.3.3 Treatment Usage Patterns 43

      5 Global Diabetes Market: Therapeutic Landscape 48

      5.1 Type 1 Diabetes Market 48

      5.1.1 Introduction 48

      5.1.2 Symptoms 48

      5.1.3 Treatment 48

      5.1.4 Unmet need 50

      5.1.5 Revenue 51

      5.1.6 Annual Cost of therapy 52

      5.1.7 Treatment Usage Patterns 54

      5.1.8 Drivers and Restraints for the Type 1 Diabetes Market 60

      5.2 Type 2 diabetes Therapeutics Market 61

      5.2.1 Introduction 61

      5.2.2 Symptoms 61

      5.2.3 Treatment 62

      5.2.4 Unmet need 62

      5.2.5 Revenue 63

      5.2.6 Annual Cost of therapy 64

      5.2.7 Treatment Usage Patterns 66

      5.2.8 Drivers and Restraints for the Type 2 Diabetes Market 72

      5.3 Revenues by Class of Drugs of Type 2 Diabetes 74

      6 Global Diabetes Market: Pipeline Analysis 77

      6.1 Introduction 77

      6.1.1 Research and Development Pipeline – Type 1 Diabetes 79

      6.1.2 Research and Development Pipeline – Type 2 Diabetes 83

      6.2 Innovations in Diabetes Treatment 94

      6.2.1 Insulin in Pills (Oral Delivery) 94

      6.2.2 Promising Treatments for Diabetic Retinopathy 94

      6.2.3 Biomarkers in Diabetes 94

      6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline 94

      6.3 Drug Delivery in Diabetes 95

      6.3.1 Factors Determining Preference for Drug Delivery 95

      6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable 95

      6.3.3 Innovation in Drug Delivery Systems 96

      6.4 Profiles of Promising Drugs in the Diabetes Market 97

      6.4.1 rhGAD65 (Diamyd) 97

      6.4.2 DiaPep277 97

      6.4.3 Otelixizumab 98

      6.4.4 Oral-lyn 99

      6.4.5 BMS-512148 (dapagliflozin) 100

      6.4.6 Victoza (liraglutide) 101

      6.4.7 D-Tagatose 103

      6.4.8 JNJ-28431754 (canagliflozin) 103

      6.4.9 MB07803 104

      7 Global Diabetes Market: Competitive Landscape 106

      7.1 Diabetes Market Overview 106

      7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth 106

      7.2 Market Share Analysis: Diabetes 107

      7.3 Competitive Profiling 108

      7.3.1 Novo Nordisk 109

      7.3.2 Sanofi-Aventis 116

      7.3.3 Takeda 121

      7.3.4 Eli Lilly 124

      7.3.5 GlaxoSmithKline (GSK) 130

      7.3.6 Merck & Co Inc 134

      7.3.7 Amylin Pharmaceuticals 137

      8 Global Diabetes Market: M&A Landscape 141

      8.1 Overview 141

      8.1.1 M&A by Geography 142

      8.1.2 M&A by Value ($) 143

      8.2 R&D Licensing Agreements 143

      8.2.1 Deals by Geography 145

      8.2.2 Deals by Value ($) 146

      9 Global Diabetes Market: Appendix 147

      9.1 Market Definitions 147

      9.2 Abbreviations 147

      9.3 Research Methodology 149

      9.3.1 Coverage 149

      9.3.2 Secondary Research 149

      9.3.3 Primary Research 149

      9.3.4 Forecasts 150

      9.3.5 Expert Panel Validation 152

      9.4 Contact Us 153

      9.5 Disclaimer 153

      9.6 Sources 1531.1 List of Tables

      Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 13

      Table 2: Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 13

      Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 15

      Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 15

      Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 16

      Table 6: Diabetes Therapeutics Market, Global, Treatment Usage Patterns(millions), 2009-2016 16

      Table 7: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2009 23

      Table 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2009-2016 24

      Table 9: Diabetes Market, The US, Revenues ($bn), 2001-2009 26

      Table 10: Diabetes Therapeutics Market, The US, Revenues ($bn), 2009-2016 26

      Table 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2009 27

      Table 12: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2009-2016 27

      Table 13: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009 28

      Table 14: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016 29

      Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2001-2009 34

      Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2009-2016 34

      Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2009 35

      Table 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2009-2016 35

      Table 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2009 36

      Table 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2009-2016 37

      Table 21: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2001-2009 41

      Table 22: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2009-2016 41

      Table 23: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 42

      Table 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 42

      Table 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2009 43

      Table 26: Diabetes Market, Japan, Treatment Usage Patterns(millions), 2009-2016 44

      Table 27: Type 1 Diabetes Therapeutics Market, Types of Insulin Regimen 49

      Table 28: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 51

      Table 29: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 51

      Table 30: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 53

      Table 31: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 53

      Table 32: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 55

      Table 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 55

      Table 34: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 64

      Table 35: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 64

      Table 36: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 65

      Table 37: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 65

      Table 38: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 67

      Table 39: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 67

      Table 40: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75

      Table 41: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76

      Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010 80

      Table 43: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010 81

      Table 44: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2010 82

      Table 45: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010 82

      Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010 84

      Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010 86

      Table 48: Diabetes Market, Global, R&D Pipeline by Phase in Type 2 Diabetes Market, Phase I, 2010 89

      Table 49: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010 92

      Table 50: Diabetes Therapeutics Markets, Factors Determining Preference of Drug Delivery in Diabetes, 2010 95

      Table 51: Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2010 95

      Table 52: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2010 114

      Table 53: Diabetes Therapeutics Market, Sanofi-Aventis, Pipeline Products, 2010 120

      Table 54: Diabetes Market, Takeda, Pipeline Products, 2010 123

      Table 55: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2010 128

      Table 56: Diabetes Therapeutics Market, GSK, Pipeline Products, 2010 133

      Table 57: Diabetes Therapeutics Market, Merck, Pipeline Products, 2010 136

      Table 58: Diabetes Therapeutics Market, Amylin, Pipeline Products, 2010 1391.2

      List of Figures

      Figure 1: Diabetes Therapeutics Market, Global, Revenue($m), 2001-2016 13

      Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 14

      Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 15

      Figure 4: Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 17

      Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 18

      Figure 6: Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 19

      Figure 7: Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 20

      Figure 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 23

      Figure 9: Diabetes Therapeutics Market, The US, Revenue ($m), 2001-2016 25

      Figure 10: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2016 27

      Figure 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns ('000), 2001-2016 28

      Figure 12: Diabetes Therapeutics Market, the US, Diseased Population ('000), 2001-2016 29

      Figure 13: Diabetes Therapeutics Market, the US, Treatment Seeking Population ('000), 2001-2016 30

      Figure 14: Diabetes Therapeutics Market, The US, Diagnosis Population ('000), 2001-2016 31

      Figure 15: Diabetes Therapeutics Market, The US, Prescription Population ('000), 2001-2016 32

      Figure 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2001-2016 34

      Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2016 35

      Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2001-2016 36

      Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Diseased Population ('000), 2001-2016 37

      Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population ('000), 2001-2016 38

      Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosis Population ('000), 2001-2016 39

      Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population ('000), 2001-2016 40

      Figure 23: Diabetes Therapeutics Market, Japan, Revenue ($m), 2001-2016 41

      Figure 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2016 42

      Figure 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2001-2016 43

      Figure 26: Diabetes Therapeutics Market, Japan, Diseased Population ('000), 2001-2016 44

      Figure 27: Diabetes Therapeutics Market, Japan, Treatment Seeking Population ('000), 2001-2016 45

      Figure 28: Diabetes Therapeutics Market, Japan, Diagnosis Population ('000), 2001-2016 46

      Figure 29: Diabetes Therapeutics Market, Japan, Prescription Population ('000), 2001-2016 47

      Figure 30: Type 1 Diabetes Therapeutics Market, Global, Unmet Need, 2010 50

      Figure 31: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2001-2016 51

      Figure 32: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 52

      Figure 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 54

      Figure 34: Type 1 Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 56

      Figure 35: Type 1 Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 57

      Figure 36: Type 1 Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 58

      Figure 37: Type 1 Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 59

      Figure 38: Type 1 Diabetes Therapeutics Market, Global, Drivers and Restraints, 2009 61

      Figure 39: Type 2 Diabetes Therapeutics Market, Global, Unmet Need, 2010 62

      Figure 40: Type 2 Diabetes Therapeutics Market, Global, Revenues ($m), 2001-2016 63

      Figure 41: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 64

      Figure 42: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 66

      Figure 43: Type 2 Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 68

      Figure 44: Type 2 Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 69

      Figure 45: Type 2 Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 70

      Figure 46: Type 2 Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 71

      Figure 47: Type 2 Diabetes Therapeutics Market , Global, Market Drivers and Barriers, 2009-2016 73

      Figure 48: Type 2 Diabetes Therapeutics Market , Global, Market Share by Class of Drugs, 2009-2016 74

      Figure 49: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75

      Figure 50: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76

      Figure 51: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 77

      Figure 52: Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 78

      Figure 53: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 79

      Figure 54: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 83

      Figure 55: Diabetes Therapeutics Market, Global, Share of Top Manufacturers (%), 2010 107

      Figure 56: Diabetes Therapeutics Market, Global, Revenue of Top Seven Players ($m), 2007-2009 108

      Figure 57: Diabetes Therapeutics Market, Novo Nordisk, Revenue Segments (%), 2009 110

      Figure 58: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Product (%), 2009 111

      Figure 59: Diabetes Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010 115

      Figure 60: Diabetes Therapeutics Market, Sanofi-Aventis, Revenue Segment (%), 2009 116

      Figure 61: Diabetes Therapeutics Market, Sanofi-Aventis, Diabetes Revenue by Product (%), 2009 117

      Figure 62: Diabetes Therapeutics Market, Sanofi-Aventis, SWOT Analysis, 2010 120

      Figure 63: Diabetes Therapeutics Market, Takeda, Revenue Segments (%), 2009 121

      Figure 64: Diabetes Therapeutics Market, SWOT Analysis, Takeda, 2010 123

      Figure 65: Diabetes Therapeutics Market, Eli Lilly, Revenue Segments (%), 2009 124

      Figure 66: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2009 125

      Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly, 2010 129

      Figure 68: Diabetes Therapeutics Market , GSK, Revenue Segments (%), 2009 130

      Figure 69: Therapeutics Market, GSK, Diabetes Revenue by Product (%), 2009 131

      Figure 70: Diabetes Therapeutics Market, GSK, SWOT Analysis, 2010 133

      Figure 71: Diabetes Therapeutics Market, Merck, Diabetes Revenue as Percentage of Total Revenue (%), 2009 134

      Figure 72: Diabetes Therapeutics Market, Merck, SWOT Analysis, 2010 136

      Figure 73: Diabetes Therapeutics Market, Amylin, Diabetes Revenue as Percentage of Total Revenue (%), 2009 137

      Figure 74: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2009 138

      Figure 75: Diabetes Therapeutics Market, Amylin, SWOT Analysis, 2010 140

      Figure 76: Diabetes Therapeutics Market, Global, Major M&As By Geography (%), n=48, 2009-2010 142

      Figure 77: Diabetes Therapeutics Market, Global, Major M&As By Value ($), n=48, 2009-2010 143

      Figure 78: Diabetes Therapeutics Market, Global, Major Licensing Agreements By Geography ($), n=76, 2009-2010 145

      Figure 79: Diabetes Therapeutics Market, Global, Major Licensing Agreement By Value ($), n=76, 2009-2010 146

      Figure 80: GBI Research Market Forecasting Model 152

      Companies mentioned

      To order this report:

      Pathology Industry: Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

      Pathology Business News

      More  Market Research Report

      Check our  Company Profile, SWOT and Revenue Analysis!

      Contact:


      Nicolas Bombourg

      Reportlinker

      Email: [email protected]

      US: (805)652-2626

      Intl: +1 805-652-2626



      SOURCE Reportlinker

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.